YD Bio Ltd(YDES)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

YD Bio Ltd (YDES) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores YDES at 24.7/100 on a 32-signal composite quality model, placing it at rank #2,682 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), YD Bio Ltd reports quarterly revenue of $596.8K, net income of $-8.3M, free cash flow of $-8.0M. Top institutional holders of YDES by reported 13-F value include Cypress Capital Management (WY), Oasis Management Ltd., Garrett Wealth Advisory Group, based on the most recent SEC filings. YDES trades on the Nasdaq exchange and files with the SEC under CIK 2011674. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate YDES daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for YD Bio Ltd directly from SEC EDGAR.